OK, you are right, the prob of FDA could grant accelerated approval or not, would be the third layer of probability calculation.
In which case, our difference boils down to whether FDA would ask the panel to recommend whether they should wait for more data, which you handicapped a 74% probability, that's way too high imo.
Market Data 
Markets 
AI
